News
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...
GlobalData on MSN16h
CHMP rejects Elevidys in latest setback for Sarepta
Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.
Sarepta says it's working with an independent group of Duchenne experts to develop an enhanced immunosuppressive regimen. In morning trades Monday, Sarepta stock crashed more than 43% to 20.51 ...
Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback